MDLN vs ONC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MDLN exhibits strong fundamental health with a Piotroski F-Score of 7/9 and exceptional liquidity (Current Ratio 4.29), suggesting a stable operational baseline. However, the stock is currently trading at a premium to its Intrinsic Value ($42.18) and significantly above its Graham Number ($20.63). This valuation gap, combined with a starkly bearish technical trend and massive insider liquidation exceeding $3.5 billion, offsets the positive analyst consensus and revenue growth.
ONC exhibits strong operational health with a Piotroski F-Score of 7/9 and a robust balance sheet characterized by low debt (D/E 0.25) and high liquidity. However, there is a severe disconnect between the current market price ($319.94) and deterministic value metrics, with the Graham Number ($47.6) and Intrinsic Value ($17.92) suggesting massive overvaluation. While the company has successfully transitioned from deep historical losses to profitability and maintains strong revenue growth (32.8%), aggressive insider selling by the CEO and a bearish technical trend offset the 'Strong Buy' analyst consensus.
Compare Another Pair
Related Comparisons
MDLN vs ONC: Head-to-Head Comparison
This page compares Medline Inc. (MDLN) and BeOne Medicines AG (ONC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.